Cantor Fitzgerald Forecasts Gilead Sciences FY2025 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Gilead Sciences in a report issued on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will earn $8.05 per share for the year, up from their prior forecast of $7.96. Cantor Fitzgerald currently has a "Overweight" rating and a $125.00 price objective on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share. Cantor Fitzgerald also issued estimates for Gilead Sciences' FY2026 earnings at $9.40 EPS.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The business's revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.32) EPS.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Finally, Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $111.38.

Gilead Sciences Price Performance

Shares of GILD opened at $113.24 on Thursday. The company has a market cap of $140.86 billion, a P/E ratio of 23.84, a PEG ratio of 0.72 and a beta of 0.29. The stock has a fifty day moving average price of $107.40 and a 200 day moving average price of $104.35. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences has a 12 month low of $67.65 and a 12 month high of $119.96.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $330,510.00. Following the sale, the insider owned 120,168 shares of the company's stock, valued at approximately $13,238,908.56. This represents a 2.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the sale, the chief financial officer directly owned 165,110 shares in the company, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds have recently added to or reduced their stakes in GILD. Brighton Jones LLC grew its holdings in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $339,000. Personal CFO Solutions LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $207,000. Johnson Investment Counsel Inc. grew its holdings in Gilead Sciences by 10.3% during the 4th quarter. Johnson Investment Counsel Inc. now owns 16,629 shares of the biopharmaceutical company's stock worth $1,536,000 after acquiring an additional 1,549 shares during the last quarter. Finally, Independent Advisor Alliance lifted its position in Gilead Sciences by 35.4% during the 4th quarter. Independent Advisor Alliance now owns 32,128 shares of the biopharmaceutical company's stock valued at $2,968,000 after purchasing an additional 8,398 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.